Samuel Beavers

Samuel Beavers

Associate
Samuel Beavers
Washington, DC
+1 202 346 4181

Sam Beavers, an associate in the firm’s Life Sciences group, concentrates his practice on complex transactions in the life sciences industry, including mergers and acquisitions, venture capital financings, joint ventures, and other strategic transactions. Sam also acts as general corporate counsel, providing guidance on commercial contracts, including collaborations and licensing arrangements, and corporate governance matters.

Experience

  • Advised ETM Electromatic, Inc. in its agreement to be acquired by Teledyne Technologies
  • 5AM Ventures and Frazier Healthcare Partners as lead investors in the creation and $30 million financing of Radionetics Oncology
  • Advised Biocon Biologics Ltd. in its $3.335 billion (cash up to $2.335 billion plus stock in BBL valued at $1 billion) agreement to acquire Viatris Inc.’s (NASDAQ: VTRS) global biosimilars business
  • Advised ModeX Therapeutics, Inc. on its sale to OPKO Health, Inc. for $300 million in OPKO common stock
  • Advised Royalty Pharma on its funding agreement and royalty acquisition with Cytokinetics for up to $450 million

Professional Experience

Prior to joining Goodwin, Sam was an associate at Ice Miller LLP.

Credentials

Education

JD2014

The Ohio State University

Moritz College of Law

(cum laude)

BA2010

The Ohio State University

Admissions

Bars

  • District of Columbia
  • Ohio

Recognition & Awards

While attending law school, Sam was a managing editor on the Ohio State Journal on Dispute Resolution.